Navigation Links
Vical to Present at Cowen and Company Health Care Conference
Date:3/12/2008

BOSTON, March 12 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) announced today that the company will present an overview of its product development programs on Monday, March 17, at the 28th Annual Cowen and Company Health Care Conference (Boston -- March 17-20).

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127

Website: http://www.vical.com


'/>"/>
SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vical to Present at BIO and BVGH Global Health Partnering Event
2. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
3. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
4. New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
5. Vical Launches Redesigned Website
6. Vical Presentation at Military Pandemic Influenza Workshop
7. Amedica Receives FDA 510(k) Clearance for Valeo(TM) Cervical Plate
8. Vical to Present at Investor Conferences
9. Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening
10. Vical Announces News Release and Conference Call Schedule for Third Quarter 2007 Financial Results
11. Nventa updates progress of cervical dysplasia trial with new HspE7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... ... The Center for Excellence in Education Sponsors Teacher Training Program , Bite of ... 2016 – The Center for Excellence in Education (CEE) will sponsor a Bite ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
(Date:2/4/2016)... 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... that Edward Lanphier , Sangamo,s president and chief ... of Sangamo,s ZFP Therapeutic ® development programs and ... pm ET on Thursday, February 11, 2016, at the ... The conference is being held in New ...
(Date:2/4/2016)... 2016  CytoSorbents Corporation (NASDAQ: CTSO ), ... CytoSorb® blood filter to treat deadly inflammation in ... announced that CEO Dr. Phillip Chan , ... Group,s 2016 Disruptive Growth & Healthcare Conference, providing ... Conference Presentation Details: Where: Convene Conference ...
Breaking Biology Technology:
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., a ... simplifies the use and access of ubiquitous on-premise ... partnership with American Cyber.  ... experience leading transformational C4ISR and Cyber initiatives in ... the latest proven technology solutions," said Steve ...
(Date:1/11/2016)...  higi, the leading retail and omni-channel community engagement ... and mobile, today announced it has closed funding ... --> --> ... higi,s health platform – its network of health ... expanding services and programs to retail partners and ...
(Date:1/7/2016)... 2016  A United States District Court in ... the country to interpret a biometric privacy statute in ... against the photo website Shutterfly brought by the law firm ... vs. SHUTTERFLY, INC.; and THISLIFE, INC ( N.D. ... violates the Illinois Biometric Privacy Act by collecting and ...
Breaking Biology News(10 mins):